ABSTRACT Human cytomegalovirus (CMV) is a common cause for human viral infection and is mostly asymptomatic in healthy individuals. However, CMV is the leading cause of congenital infection and is a common opportunistic pathogen in immunocompromised individuals. The currently approved antivirals have limited efficacy due to the development of resistance and severe toxicities. It is thus imperative to develop new therapeutics that are highly efficacious and without significant toxicities. The purpose of this review is to provide genotypic maps of drug resistance mutations, give an update of the progress of CMV antiviral drug resistance research, and showcase promising drug candidates.
View Full Article
|